The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index; none of the 29 sources its claims cite is checked for support yet.
Abstract
The tumor suppressor protein p53 (TP53) is frequently mutated in various types of human malignancies, including HNSCC, which affects tumor growth, prognosis, and treatment. Gaining insight into the impact of TP53 mutations in HNSCC is crucial for developing new diagnostic and therapeutic methods. In this study, we aimed to investigate the influence of mutations on the structure and functions of the TP53 protein and miRNA expression using computational analysis. The genomic data of patients with HNSCC were obtained from TCGA, and the impact of mutations on the TP53 gene was investigated using different bioinformatics tools. Results: The findings showed that the TP53 mutations increased TP53 expression levels in HNSCC and were associated with a poor prognosis. Furthermore, hsa-mir-133b expression was reduced in TP53-mutated samples, significantly affecting patient survival in HNSCC. Six mutations, including R273C, G105C, G266E, Q136H/P, and R280G, were identified as deleterious, carcinogenic, driver, highly conserved, and exposed. These mutations were located in the P53 domain, and PTM analysis revealed that R280G and R273C are at a methylation site, and R273C, Q136H/P, and R280G are located in the protein pocket. The docking research indicated that these mutations decreased the binding affinity for DNA, with R273C, R280G, G266E, and G105C displaying the most significant differences. The molecular dynamics analysis indicates that R280G, Q136H, and G105C mutations confer a gain of function by stabilizing the TP53-substrate complex. Conclusions: Based on the research findings, the mutations on TP53 were found to have an impact on protein and miRNA expression, development, survival, and progression of HNSCC patients, and has-mir-133b could be a promising novel biomarker for monitoring the progression of HNSCC. It was discovered that G105C and Q136H/P, as novel mutations, affect the function and structure of proteins causing HNSCC, which indicates that they could be interesting subjects for further investigation, diagnostics, and therapeutic strategies. Furthermore, the precise positioning of R280G and R273C within the methylation site and Q136H/P in the binding site has been documented for the first time. Moreover, the G105C, Q136H, and R280G mutations that stabilized TP53 structure and altered its interaction dynamics with substrates may serve as novel potential diagnostic biomarkers in cancer, guiding patient stratification and personalized treatment strategies. The molecular dynamics analysis provides insights into how specific TP53 mutations impact protein structure, stability, and function upon substrate binding, highlighting their role in cancer biology and potential implications for therapeutic interventions. This paper provides a novel understanding of the mechanisms by which these mutations contribute to the development of cancer.
Overview
CoChat Summary
TL;DR
This in silico study analyzed TCGA HNSCC data and found TP53 mutations in 70% of 1,332 samples, associated with disease presence and reduced progression-free survival, with hsa-mir-133b downregulation linked to poorer survival. It prioritized six TP53 missense mutations (R273C, G105C, G266E, Q136H/P, R280G) as deleterious/driver/cancer-associated, with structural, docking, and molecular-dynamics evidence of altered DNA binding and stability.
Key findings
- Among 319 TP53 mutations identified, missense mutations were most frequent (146), followed by 78 frameshifts, 40 splicing, 39 stop-gained, 9 inframe deletions, 6 synonymous, and 1 intron mutation; 226 substitutions, 24 insertions, and 76 deletions were found.
- Out of 1,332 samples, 932 (70%) showed TP53 mutations. Table 1 reports altered-group survival associations: overall p=1.42E-06, disease-free p=5.28E-03, progression-free p=0.0102, and disease-specific p=0.0349; the text highlights significant association with HNSCC presence (P=0.0349) and reduced progression-free survival (P=0.0102).
- TP53 expression was increased in TP53-mutant and nonmutant HNSCC samples versus normal tissues, but this increase had no significant survival impact (Fig 3B, P=0.12). hsa-mir-133b was significantly downregulated in both mutant and nonmutant groups and associated with poorer survival (P=0.017); hsa-mir-183 was elevated without significant survival impact (P=0.67); hsa-mir-145 was upregulated with near-significant survival correlation (P=0.056).
- Six mutations—R273C, G105C, G266E, Q136H/P, and R280G—were identified as deleterious, carcinogenic, driver, highly conserved, and exposed, located in the P53 domain. Docking showed decreased binding affinity, with R273C, R280G, G266E, and G105C displaying the most significant differences; MD showed Apo-TP53 RMSD 26.20 Å versus wild-type 3.48 Å, and mutants G105C 3.74 Å, Q136H 4.79 Å, R280G 4.86 Å, with R280G having the lowest hydrogen-bond formation rate (0.024 ns⁻¹ vs wild-type 0.0360 ns⁻¹).
Methods
- Data were obtained from TCGA via the Genomic Data Commons and cBioPortal, using three HNSCC studies: TCGA Firehose Legacy (530 samples), TCGA Nature 2015 (279 samples), and TCGA Pan Cancer Atlas (523 samples). UALCAN was used to assess TP53 and miRNA-seq expression (hsa-mir-183, hsa-mir-133b, hsa-mir-145) in relation to TP53 mutations.
- Mutation impact was assessed with multiple in silico tools: VEP, SIFT, Polyphen, PhD-SNP, PANTHER, SNPs&GO, CScape, CScape-somatic, FATHMM, I-Mutant2.0, CUPSAT, MUpro, ConSurf, Mutation3D, GPS 5.0/GPS-MSP, CASTp, SOPMA, HOPE, and UCSF Chimera. PPI networks were built with STRING and visualized in Cytoscape.
- Structural analyses included docking with AutoDock, HDock, and pyDOCK using PDB 2AC0, and molecular dynamics simulations with NAMD/VMD using TIP3P solvation, 200 ns simulations, 100,000,000 steps, 310 K, NVE ensemble, and PME for long-range electrostatics.
Limitations
- Stated in the paper: the study is based entirely on in silico analyses, and no experimental validation was conducted to confirm the computational predictions.
- Stated in the paper: the dataset primarily uses publicly available TCGA data, which may not represent all demographic and geographic populations affected by HNSCC.
- Evident from the text: the findings rely on multiple computational prediction tools and public datasets, and the authors call for experimental validation, development of therapies targeting key TP53 mutations, integration of mutation profiling into clinical practice, and expanded analysis across diverse populations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
0 Valid · 1 Not valid · 29 Not checked · 139 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The findings showed that the TP53 mutations increased TP53 expression levels in HNSCC and were associated with a poor prognosis.”
- Also stated in: § 3.3. The TP53 gene mutations and miRNA expression analysis of HNSCC patients · plain
“In HNSCC patients, the expression of the mutant TP53 gene was increased, however, this increase had no significant impact on the survival of HNSCC patients Fig 3A and B.”
§ The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 3.3. The TP53 gene mutations and miRNA expression analysis of HNSCC patients · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The findings showed that the TP53 mutations increased TP53 expression levels in HNSCC and were associated with a poor prognosis.”
- Also stated in: § 3.2. Genomic alterations of TP53 in HNSCC patients · hedged
“reduced progression-free survival (P = 0.0102), suggesting that TP53 mutations may be linked to more aggressive or treatment-resistant forms of HNSCC.”
§ The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies > Abstract
plainstates an associationn = 1,332 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 3.2. Genomic alterations of TP53 in HNSCC patients · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The study demonstrated that the six mutations altered the secondary structure, including the alpha helix, extended strand, turn, and coil.”
§ The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies > 3. Results > 3.4. Mutations analysis
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The prediction of the impact of TP53 mutations on stability revealed that the six mutations decrease protein stability as determined by I-MUTANT 2.0, MUpro, and CUPSAT triple software Table 4.”
§ The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies > 3. Results > 3.4. Mutations analysis
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the expression of hsa-mir-183 was elevated in both mutant and non-mutant TP53 groups”
§ The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies > 3. Results > 3.3. The TP53 gene mutations and miRNA expression analysis of HNSCC patients
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
102 more claims
Create a free account to see all 169 claims and to verify the 29 references still open.
- It may state two separate claims as one. 53
- Probably not a substantial claim. 13
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies > Abstract
“The molecular dynamics analysis indicates that R280G, Q136H, and G105C mutations confer a gain of function by stabilizing the TP53-substrate complex.”
§ The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies > 3. Results > 3.4. Mutations analysis
“All tested mutations resulted in a relative increase in average RMSD compared to wild-type TP53 (3.48 Å), suggesting potential destabilization of the protein-DNA complex structures.”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies > 3. Results > 3.2. Genomic alterations of TP53 in HNSCC patients
“932 (70%) showed TP53 mutations, which were significantly associated with both the presence of HNSCC (P = 0.0349), indicating that patients with these mutations are more likely to develop the disease, and with reduced progression-free survival (P = 0.0102)”
§ The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies > 3. Results > 3.2. Genomic alterations of TP53 in HNSCC patients
“| Disease-specific | 497 | 338 | 0.0349 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“The analysis revealed a total of 319 mutations in the TP53 gene. These mutations were categorized into seven types: 78 frameshifts, 146 missense, nine inframe deletions, one intron mutation, six synonymous, 39 stop-gained mutations, and 40 splicing (including donor, acceptor, and region) (Fig 1A and B). In these mutations, 226 substitutions, 24 insertions, and 76 deletions were found S1 Data.”
§ The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies > 3. Results > 3.1. Data analysis
Reported 319 · recomputed 326
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies > 3. Results > 3.1. Data analysis
“These mutations were categorized into seven types: 78 frameshifts, 146 missense, nine inframe deletions, one intron mutation, six synonymous, 39 stop-gained mutations, and 40 splicing (including donor, acceptor, and region) (Fig 1A and B).”
§ The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies > 3. Results > 3.4. Mutations analysis
“A total of 118 out of 145 mutations were found to have significant impact, moderate effect, harmful, and likely damaging effects by VEP, SIFT, and Polyphen were retrieved S2 Data and analysed by PhD-SNP, PANTHER and, SNPs&GO.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies > 4. Discussion
“missense mutations are the most frequently observed type among six different mutation types, including frameshift mutations and inframe deletions in HNSCC”
§ The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies > 3. Results > 3.1. Data analysis
“These mutations were categorized into seven types: 78 frameshifts, 146 missense, nine inframe deletions, one intron mutation, six synonymous, 39 stop-gained mutations, and 40 splicing (including donor, acceptor, and region) (Fig 1A and B).”
1 more finding
Create a free account to see every finding of this check.
Citations
Cites
VMD: visual molecular dynamics
Humphrey, W., Dalke, A., & Schulten, K. (1996) · Journal of Molecular Graphics · doi:10.1016/0263-7855(96)00018-5 · Cited by 66,952
Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N. T., Morris, J. H., Bork, P., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1131 · Cited by 17,749
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
Chandrashekar, D. S., Bashel, B., Balasubramanya, S. A. H., Creighton, C. J., Ponce-Rodriguez, I., Chakravarthi, B. V. S. K., & Varambally, S. (2017) · Neoplasia · doi:10.1016/j.neo.2017.05.002 · Cited by 6,086
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Ashkenazy, H., Abadi, S., Martz, E., Chay, O., Mayrose, I., Pupko, T., & Ben-Tal, N. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw408 · Cited by 3,163
Scalable molecular dynamics on CPU and GPU architectures with NAMD
Phillips, J. C., Hardy, D. J., Maia, J. D. C., Stone, J. E., Ribeiro, J. V., Bernardi, R. C., Buch, R., Fiorin, G., Hénin, J., Jiang, W., et al. (2020) · The Journal of Chemical Physics · doi:10.1063/5.0014475 · Cited by 3,144
The molecular landscape of head and neck cancer
Leemans, C. R., Snijders, P. J. F., & Brakenhoff, R. H. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.11 · Cited by 1,395
Rivlin, N., Brosh, R., Oren, M., & Rotter, V. (2011) · Genes & Cancer · doi:10.1177/1947601911408889 · Cited by 1,033
Cheatham, T. E. I., Miller, J. L., Fox, T., Darden, T. A., & Kollman, P. A. (1995) · Journal of the American Chemical Society · doi:10.1021/ja00119a045 · Cited by 859
Research works printed but not linked: 4
- Zhang Y, Dai Y, Liu S, et al. Exome and whole-genome sequencing identified frequent and unique mutations in head and neck squamous cell carcinoma. Front Genet. 2021; 12: 721315. doi: 10.3389/fgene.2021.721315 · doi:10.3389/fgene.2021.721315
- The Cancer Genome Atlas Research Network. The Cancer Genome Atlas (TCGA): exploring the DNA of cancer. Nat Rev Cancer. 2013; 13(10): 714– 26. doi: 10.1038/nrc3587 24060863 · DOI
- Smith JA. Docking analysis using AutoDock and HDock Server. J Comput Chem. 2020; 25(4): 123– 45. doi: 10.1234/jcc.2020.5678 · doi:10.1234/jcc.2020.5678
- Smith J, Doe A. Analysis of TP53-related genes and their interactions. J Mol Biol. 2023; 120(3): 456- 467. doi: 10.1016/j.jmb.2023.01.012 · doi:10.1016/j.jmb.2023.01.012
Cited by
Pettenger-Willey, C. M., Laszlo, G. S., Gang, M., Cole, F. M., Godwin, C. D., Erraiss, S., Chanana, P., Kehret, A. R., Li, J., Barton, J. W., et al. (2025) · Cancers · doi:10.3390/cancers18010067 · Cited by 1
Wang, Y., Yant, J. E., & Pan, X. (2026) · Cancers · doi:10.3390/cancers18132136
Pacht, E., Warren, J., Toor, R. H., Glass, K. C., Greenyer, H. W., Rodriguez, P. D., Kugler, C., Fritz, A. J., Banerjee, B., Ghule, P. N., et al. (2026) · Non-Coding RNA · doi:10.3390/ncrna12060043
Kang, K., Lim, H., Kim, J., & Kim, D. K. (2026) · Oral Biology Research · doi:10.21851/obr.26.017
Metadata
- Authors
- Mahmoud, A. A., Raih, M. F., Sage, E. E., Ali, Q. M., Suliman, O. H., Ibrahim, S. A. E., Mohamed, O., Abdelrazeg, S., & Mohamed, S. B.
- Affiliations
- National University (SD)
- National University of Malaysia (MY)
- Corresponding author
- Mohamed, Sofia B.
- Venue
- PLOS One
- Publisher
- Public Library of Science (PLoS)
- Published
- 2025-05-07
- Volume
- 20
- Issue
- 5
- Pages
- e0307859
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC12057960
- OpenAlex
- W4410153493
- Semantic Scholar
- a2d812ab8bee67c2384f4dfe3c92e378e98ddbf0
- Cited by
- 4
- References
- 31
- Citations by year
- 2026: 3 · 2025: 1
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Open Access Institutional Repository at Robert Gordon University (Robert Gordon University) (publishedVersion, other-oa)
- Open Access Institutional Repository at Robert Gordon University (Robert Gordon University) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Universiti Kebangsaan Malaysia ((DIP-2023-XX))
- National University-Sudan (NUSU, 2022,007)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Keywords
- TP53 mutation, head and neck squamous cell carcinoma, microRNA expression, protein-DNA binding affinity, gain-of-function mutations, prognostic factors
- MeSH terms
- Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Humans, Mutation, Prognosis, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, MicroRNAs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-22, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-22 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies. https://app.cochat.ai/papers/10.1371/journal.pone.0307859
- The paper
- Mahmoud, A. A., Raih, M. F., Sage, E. E., Ali, Q. M., Suliman, O. H., Ibrahim, S. A. E., Mohamed, O., Abdelrazeg, S., & Mohamed, S. B. (2025). The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies. PLOS One. https://doi.org/10.1371/journal.pone.0307859
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.